Digest Network Come funziona
Network
/
Società
Ar
Non verificato

Arrowhead Pharmaceuticals, Inc.

Di cosa scriviamo

BiotecnologiaCardiologiaFarmaceuticaMedicina - VarieSalute

98 comunicati stampa

Guarda tutti i comunicati
14/10/2026
Terza età
Biotecnologia
Farmaceutica
Salute
Vetrine/Shopping
Medicina - Varie
Web e Social Network
Industria
Arrowhead Pharmaceuticals Announces ARO-MAPT Interim Phase 1/2a Clinical Data Demonstrating Deep and Durable Tau Reductions in Healthy Volunteers
Fonte
Arrowhead Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
07/10/2026
Industria
Cardiologia
Biotecnologia
Igiene alimentare
Salute
Sanità
Comunicazione
Farmaceutica
Medicina - Varie
Arrowhead Pharmaceuticals Granted Entry in the FDA STAR Pilot Program for Plozasiran in Severe Hypertriglyceridemia
Fonte
Arrowhead Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
29/09/2026
Web e Social Network
Industria
Salute
Biotecnologia
Medicina - Varie
Farmaceutica
Arrowhead Pharmaceuticals to Host a Webinar with Interim Clinical Data from a Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer’s Disease and Other Tauopathies
Fonte
Arrowhead Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
15/09/2026
Scienza
Igiene alimentare
Biotecnologia
Medicina - Varie
Cardiologia
Sanità
Farmaceutica
Salute
Industria
Arrowhead Pharmaceuticals Announces Interim Topline Clinical Data for the First Dual-Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia
Fonte
Arrowhead Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
03/09/2026
Eventi
Web e Social Network
Cardiologia
Biotecnologia
Farmaceutica
Sanità
Salute
Medicina - Varie
Arrowhead Pharmaceuticals to Participate in Upcoming September 2026 Investor Conferences
Fonte
Arrowhead Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
30/08/2026
Web e Social Network
Eventi
Industria
Scienza
Igiene alimentare
Biotecnologia
Medicina - Varie
Cardiologia
Salute
Farmaceutica
Arrowhead Pharmaceuticals Presents Phase 3 SHASTA-3 and SHASTA-4 Data Demonstrating Plozasiran Reduced Acute Pancreatitis Events in Patients with Severe Hypertriglyceridemia
Fonte
Arrowhead Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
24/08/2026
Eventi
Web e Social Network
Scienza
Sanità
Farmaceutica
Oncologia
HIV, AIDS e malattie autoimmuni
Biotecnologia
Medicina - Varie
Cardiologia
Igiene alimentare
Salute
Arrowhead Pharmaceuticals to Present New Clinical Data at the European Society of Cardiology Congress
Fonte
Arrowhead Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
17/08/2026
Industria
Biotecnologia
Farmaceutica
Salute
Medicina - Varie
People Living with Familial Chylomicronaemia Syndrome (FCS) in Germany Have Access to REDEMPLO® (plozasiran) as a New Treatment Option to Reduce Triglycerides
Fonte
Arrowhead Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
04/08/2026
Web e Social Network
Telefonia e Varie
Eventi
Mercato azionario
Cardiologia
Biotecnologia
Farmaceutica
Salute
Igiene alimentare
Medicina - Varie
Arrowhead Pharmaceuticals Reports Fiscal 2026 Third Quarter Results
Fonte
Arrowhead Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
04/08/2026
Biotecnologia
Igiene alimentare
Salute
Farmaceutica
Medicina - Varie
Arrowhead Pharmaceuticals Acquires FDA Priority Review Voucher
Fonte
Arrowhead Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0